What's Happening?
The U.S. healthcare system is experiencing increased consolidation among providers, leading to higher costs. Hospital systems and provider networks are utilizing 'anticompetitive contracts' to restrict insurers' ability to negotiate better prices or steer
patients towards more affordable care. These contracts include 'all-or-nothing' clauses, which mandate insurers contract with all facilities in a health system, and 'anti-tiering' or 'anti-steering' clauses, which prevent insurers from incentivizing patients to choose lower-cost providers. 'Most Favored Nation' (MFN) contracts also exist, where dominant insurers demand the lowest price from providers, potentially increasing prices for other insurers. While the Federal Trade Commission (FTC) and the Department of Justice (DOJ) have authority to address anticompetitive behaviors, they have largely failed to block or reverse mergers, with the FTC preventing only 13 out of 1,300 hospital mergers in the past two decades. This consolidation and the use of such contracts contribute to rising healthcare expenditures, which are projected to reach $9 trillion by 2034.
Why It's Important?
The prevalence of anticompetitive contracts significantly impacts healthcare costs for individuals, businesses, and the federal government. These practices reduce market competition, allowing consolidated hospital systems to raise prices without improving the quality of care. Consumers face higher premiums and out-of-pocket expenses as insurers pass on increased costs. For the federal government, higher commercial prices can increase the cost of programs like the Federal Employees Health Benefits program, Medicare, and Medicaid. Additionally, the tax exemption for employer-sponsored health insurance premiums means that higher premiums reduce federal tax collections. A federal ban on these contracts could modestly lower employer-sponsored insurance premiums by 0.1%, reduce National Health Expenditures by approximately $25 billion, and decrease the federal deficit by $7 billion over the next decade (2027-2036). This would represent a step towards making healthcare more affordable and improving market fairness.
What's Next?
Federal legislative action, such as the 'Healthy Competition for Better Care Act' (H.R. 6248) introduced by Representative Arrington (R-TX), proposes banning all four types of anticompetitive contracts: all-or-nothing, anti-steering, anti-tiering, and MFN clauses. The Congressional Budget Office (CBO) previously estimated that a similar predecessor bill (H.R. 3120) would lower premiums by 0.1% and reduce the deficit by about $5 billion through 2034, primarily due to increased tax collection from employers shifting compensation to taxable wages. While these savings are considered modest, partly because some states already have similar bans, a federal ban could build upon existing state efforts. Future steps could involve coupling such bans with other reforms, including empowering the FTC and DOJ to prevent consolidations, improving price transparency, limiting provider non-compete clauses, and adopting site-neutral payments in Medicare, which could lead to more substantial price reductions.
Beyond the Headlines
The issue of anticompetitive contracts highlights a broader systemic challenge within the U.S. healthcare market: the tension between consolidation for efficiency and the need for robust competition to control costs. While some argue that mergers can lead to improved care coordination, data suggests that consolidation often results in higher prices without a corresponding improvement in quality. The federal government's historical difficulty in blocking mergers, with only 0.1% of hospital mergers prevented by the FTC, underscores the need for more effective antitrust enforcement. The reliance on state-level actions to address these contracts also points to a fragmented regulatory landscape. A comprehensive federal approach could standardize protections against these practices nationwide, fostering a more equitable and cost-effective healthcare environment. This development could also spark further debate on the role of federal intervention in regulating market practices within essential sectors like healthcare.
